Antofloxacin is a well-tolerated, orally active, and broad-spectrum 8-amino-fluoroquinolone compound that exhibits potent antibacterial properties. It demonstrates superior activity against gyrA mutation-positive Helicobacter pylori strains, particularly in strains with mutations in the Asn87 position, when compared to levofloxacin. Additionally, Antofloxacin acts as a weak but reversible inhibitor of CYP1A2 and is clinically used to treat infections caused by various bacterial species.

Administered subcutaneously to mice at doses ranging from 2.5 to 160 mg/kg over a 24-hour period, antofloxacin's penetration ratio for total drug concentrations varied between 1.22 and 1.54, showing no relation to the dosage levels [3]. Additionally, antofloxacin elevates plasma theophylline levels by functioning as a mechanism-based inhibitor of the CYP1A2 enzyme. This inhibition effect on the formation of the three metabolites of theophylline demonstrates a dependency on time, concentration, and the presence of NADPH, indicative of mechanism-based inhibition [2].